Stevens Capital Management’s bluebird bio BLUE Stock Holding History

Stevens Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-448	Closed	-$847K	–	708
2018 Q3	$847K	Buy	+448	New	+$926K	0.03%	453
2017 Q3	–	Sell	-1,274	Closed	-$1.73M	–	854
2017 Q2	$1.73M	Buy	+1,274	New	+$1.54M	0.07%	336
2015 Q4	–	Sell	-572	Closed	-$634K	–	931
2015 Q3	$634K	Sell	572 -137	-19%	-$250K	0.03%	465
2015 Q2	$1.55M	Buy	+709	New	+$1.44M	0.06%	338

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stevens Capital Management's BLUE Position: Q4 2018 in Review

Stevens Capital Management sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 448 shares — an estimated $847K sold.

Stevens Capital Management first reported a position in BLUE in Q2 2015 and held it in 4 quarters. The position peaked at $1.73M in Q2 2017. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

Stevens Capital Management reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
Stevens Capital Management sold 448 bluebird bio shares in Q4 2018, an estimated $847K.
Stevens Capital Management first reported a position in bluebird bio in Q2 2015 and held it in 4 quarters.
Stevens Capital Management's bluebird bio position peaked at $1.73M in Q2 2017.
251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Stevens Capital Management's 13F filing for Q4 2018, filed 6 Feb 2019.